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Background
Non-clinical and clinical combination studies with
GVAX and live-attenuated, double-deleted (LADD)
Listeria monocytogenes strains engineered to express
tumor-associated antigens resulted in survival benefit
and induction of cellular mediated immune responses.
Methods
In a Phase IIa randomized study, patients with meta-
static pancreatic ductal adenocarcinoma (PDA) treated
sequentially with two vaccine-based immunotherapies
demonstrated extended overall survival (OS) with tol-
erable side effects. Treatment included low-dose cyclo-
phosphamide (CY) followed by GVAX pancreas, an
irradiated GM-CSF-secreting allogeneic PDA cell vac-
cine, and subsequent administrations of CRS-207, a
LADD vaccine engineered to express mesothelin. Study
inclusion criteria were diagnosis of metastatic PDA,
refusal or receipt of > 1 prior chemotherapy, ECOG 1
and adequate organ function. 90 patients were rando-
mized 2:1 to receive 2 doses of CY/GVAX followed by
4 doses of CRS-207 (Arm A, median OS 6.1 months)
or 6 doses of CY/GVAX (Arm B, median OS
3.9 months) (HR=0.54, one-sided p=0.011).
Results
As of June 2015, 7 patients remain alive. Two patients
continue on treatment: 1 original Arm A treatment
(35.6 months on treatment); 1 Arm B on the 4th
course of rollover treatment (32 months on treatment).
Five patients are currently in follow-up (Arm A) with a
median time since first treatment of 36.1 months
(range, 30.0 to 39.5 months). Peripheral blood mono-
nuclear cells and serum were collected at baseline and
over the course of treatment for immune monitoring
and biomarker analysis. Here we report systematic cel-
lular immunophenotyping and serum protein profiling
in a sub-cohort of 38 PDA patients enrolled in this
study. Mass cytometry and Luminex analysis of this
sub-cohort revealed candidate biomarkers at baseline
that were predictive of clinical outcome. Analysis of
longitudinal time points using mass cytometry, flow
cytometry, Luminex, Western blotting and ELISA are
ongoing to identify mechanistic biomarkers that corre-
late with survival.
Conclusions
These findings may inform future efforts to identify
patients with productive responses that are most likely
to benefit from immune-based therapy.
Clinical trial information NCT01417000.
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